Webinars/Videos

Prof Bhatt answers questions received from the audience before and during the live webinar on Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial.

For the best learning experience, we recommend watching the KOL masterclass on/demand video in addition to this video.

Prof. Deepak Bhatt

First published: March 26, 2022  

In this masterclass on demand video, Prof Bhatt discusses Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention: The REDUCE-IT Trial.
This masterclass on-demand video is designed for health care professionals (cardiologists, endocrinologists, lipidoligists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment and clinical management in reducing cardiovascular events with Icosapent Ethyl-Intervention.

Prof. Deepak Bhatt

First published: March 26, 2022  

Prof. Tokgözoğlu answers questions received from the audience during the live webinar on Atherosclerotic Cardiovascular Disease (ASCVD) and dyslipidemia in female patients. For the best learning experience, we recommend watching the KOL masterclass on-demand video in addition to this video.

Prof. Lale Tokgözoğlu

First published: March 7, 2022  

In this KOL masterclass on-demand video, Prof. Lale Tokgözoğlu discusses Atherosclerotic Cardiovascular Disease (ASCVD) and dyslipidemia in female patients with emphasis on female specific risks, course, and management of the disease.

This masterclass on-demand video is designed for health care professionals (cardiologists, endocrinologists, lipidogists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with a history and risk of ASCVD.

Prof. Lale Tokgözoğlu

First published: March 7, 2022  

Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.

To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.

Prof. Christopher Cannon, Prof. Kausik Ray

First published: January 10, 2022  

Listen to the first of a free series of webinars brought to you by the Wiley Knowledge Hub on ASCVD and Lipidology.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

Listen to Prof. Lale Tokgözoğlu summarizing the year in Lipids and discussing the highlights from this year’s AHA Scientific Sessions.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

Prof. Chern-En Chiang talks about some of the recent advances in diabetes treatment in patients with ASCVD.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

Listen to our key opinion leaders, Prof. Lale Tokgözoğlu and Prof. Chern-En Chiang answer audience questions on ASCVD and Lipidology.

Prof. Lale Tokgözoğlu, Prof. Chern-En Chiang

First published: December 13, 2021  

A Peer-to-Peer Discussion

In this specially compiled video, Dr. Carl Orringer, a past president of the National Lipid Association (NLA), shares his views on the recently published NLA Scientific Statement on Lipid Measurements in the Management of Cardiovascular Diseases in a conversation with our Editorial Panel Member, Prof. Lale Tokgözoğlu. The experts discuss the importance of these lipoprotein measurements to clinicians and other healthcare professionals providing treatment and the importance of shared decision making (SDM) in improving patient care.

Prof. Lale Tokgözoğlu, Dr. Carl Orringer

First published: October 21, 2021  

A comprehensive summary of the highlights from ESC Congress 2021 in ASCVD and lipidology. In this specially compiled video, Professor Cannon and Professor Bhatt share their views on the late breaker results from REDUCE-IT and OMENI trials, along with the update ESC prevention guidelines.

Christopher Cannon, MD & Dr. Deepak L. Bhatt MD, MPH

First published: September 16, 2021  

In this second video from the ESC 2021, Professor Cannon and Professor Nicholls discuss late-breaking results from the HUGYENs trial on evolcoumab, as well as the ESC prevention guidelines and the impact of the NHS approval of Inclisiran in improving patient care.

Christopher Cannon, MD & Professor Stephen Nicholls, MBBS, Ph.D., FRACP, FACC, FESC, FAHA, FCSANZ, FAHMS

First published: September 15, 2021